IMMU
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
Lue lisääLiikevaihto milj.
EBIT-% (oik.)
EPS (oik.)
Osinko %
Osavuosikatsaus Q2'26
Osavuosikatsaus Q3'26
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
